Background The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …

Importance Dose-reduced regimens of direct oral anticoagulants (DOACs) may be used for
2 main purposes: dose-adjusted treatment intended as full-intensity anticoagulation (eg, for …

Cancer-associated thrombosis (CT) is associated with a high risk of recurrent venous
thromboembolic (VTE) events that require extended anticoagulation in patients with active …

Background There are no data on the effect of low‐dose anticoagulation as secondary
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …

Drug–drug interactions (DDIs) are common in cancer management and complicate the
choice of anticoagulation in cancer‐associated thrombosis. Cancer confers an increased …

Venous thromboembolism (VTE) is a common complication in patients with cancer. The risk
of emergent VTE is four-to seven-fold higher in cancer patients compared to non-cancer …

The concept of pulmonary embolism is evolving. Recent and emerging evidence on the
treatment of specific patient populations, its secondary prevention, long-term complications …

Venous thromboembolism is a leading cause of morbidity and mortality in patients with
active cancer who require anticoagulation treatment. Choice of anticoagulant is based on …

Cancer-associated thrombosis (CAT) poses a significant disease burden and the incidence
in Asian populations is increasing. Anticoagulation is the cornerstone of treatment, but can …

Simple Summary Venous thromboembolism (VTE) is a common and often fatal complication
in cancer patients. The initial treatment for VTE in cancer patients is typically low molecular …